Amine Oxidase Platform
There is significant interest among leading clinicians and pharmaceutical companies in inflammatory and fibrotic diseases. Pharmaxis’ amine oxidase platform enables the synthesis of inhibitors with different pharmacological and pharmacokinetic profiles to potentially treat a number of inflammatory and fibrotic diseases.
The inhibition of amine oxidase based enzymes has broad potential applications.
While Pharmaxis’ primary focus is the development of PXS-5505 for myelofibrosis, the drug also has potential in several other cancers including liver and pancreatic cancers where it aims to breakdown the fibrotic tissue in the tumour and enhance the effect of existing chemotherapy.
Other drugs in development include:
- PXS-5382 (LOXL2 inhibitor) – anti fibrotic drug for CKD, IPF, NASH
- PXS-6302 (topical pan LOX inhibitor) - anti fibrotic drug for skin scarring including burns, established scars, and keloids
- PXS-4699 (dual SSAO/MAOB inhibitor) – anti inflammatory drug for muscular dystrophies such as DMD
- PXS-5370 (dual SSAO/MPO inhibitor) - anti inflammatory drug for multiple indications.
- PXS-4728 (SSAO inhibitor) - anti inflammatory drug currently being assessed for potential clinical applications.